# A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women

> **NCT07118085** · PHASE1 · RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Healthy Postmenopausal Women

## Interventions

- **DRUG:** experimental Arm IMC-003
- **DRUG:** The placebo Arm: The placebo of IMC-003

## Key facts

- **NCT ID:** NCT07118085
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118085, "A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07118085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*